SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing a sharp sell-off following the announcement that Marvell cancelled purchase orders due to an alleged breach of confidentiality triggered by recent public comments from the company's CFO. While the community remains deeply divided between those calling the stock a fundamental failure and others who view the dip as a tactical buying opportunity, the primary concern is the potential erosion of trust with future hyperscale partners.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing heightened volatility as the community debates its long-term AI strategy, driven by reports that OpenAI may partner with the company to develop custom smartphone processors. Investors remain divided, with some betting on a reversal and AI-driven growth, while others express frustration over recent price fluctuations and persistent short-term bearish sentiment.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is experiencing significant volatility and heavy trading volume as investors debate whether a long-standing insider selling overhang from AE Industrial Partners has finally cleared. The community remains deeply divided, with bulls pointing to strong contract wins and potential tailwinds from the broader space economy, while bears remain skeptical about consistent execution and continued selling pressure.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following a positive readout for its late-stage HAE study, which bolstered the bull case for its in vivo CRISPR platform despite intense scrutiny from shorts. Investors are heavily focused on the implications for future drug adoption, institutional positioning, and the potential for a significant short squeeze as the company moves toward regulatory milestones.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is seeing intense volatility and social media discussion driven by frequent trading halts and speculation regarding its business model and recent strategic management changes. The community remains deeply divided, with some traders focused on momentum and potential short-squeeze dynamics, while others express significant skepticism about the company's financial structure and long-term outlook.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is trending as investors weigh the significant valuation disconnect between its recent acne trial success and its current market capitalization, while speculation intensifies regarding potential acquisition interest from larger players in the MASH space. Community sentiment remains split between long-term confidence in the drug's multi-indication pipeline and short-term frustration over price volatility and the lack of immediate monotherapy funding for its MASH program.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is seeing heightened volatility as the community debates a potential double-top formation near $79,000 against optimistic sentiment surrounding institutional ETF inflows and corporate treasury accumulation. Market participants are intensely focused on key technical resistance levels and upcoming macroeconomic catalysts, with social discourse split between bullish expectations for a breakout and bearish warnings of a deeper liquidity flush.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is experiencing heightened volatility following an unverified report alleging the cancellation of a major contract, which the community is debating as a potential market manipulation attempt or "hit job" by short sellers. Traders are closely monitoring the stock ahead of upcoming earnings, while discussions remain polarized between those dismissing the negative news as FUD and those concerned about the company's long-term leadership and transparency.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors anticipate a major oral presentation of its pancreatic cancer trial data at the upcoming Digestive Disease Week (DDW), which the community views as a critical catalyst for valuation. Traders are actively discussing the stock's clinical progress, institutional accumulation, and the potential for the company to emerge as a key player in the oncology market.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a major leadership overhaul, including the departure of former CEO Peter Greenleaf and the appointment of Chairman Kevin Tang to lead the company. The community is buzzing with optimism that this management pivot, paired with Tang's aggressive cost-cutting measures, signals a strategic shift aimed at accelerating a potential buyout.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With Profusa Stock Tuesday?

Profusa ($PFSA) shares down 40% to $1.10. Company signs LOI for $30M acquisition to scale its diagnostics and monitoring business.read more...

Small Cap Stocks To Consider - April 6th

Inflection Point Acquisition, XIAO-I, Profusa, Direxion Daily MU Bull 2X Shares, Aehr Test Systems, SMX (Security Matters) Public, and Spring Valley Acquisition are the seven Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of companies wit...

Top Manufacturing Stocks To Consider - April 6th

Taiwan Semiconductor Manufacturing, Profusa, and Applied Materials are the three Manufacturing stocks to watch today, according to MarketBeat's stock screener tool. Manufacturing stocks are shares of...

Medical Stocks To Watch Today - April 6th

Hologic, Soleno Therapeutics, Eli Lilly and Company, UnitedHealth Group, Profusa, Johnson & Johnson, and Amgen are the seven Medical stocks to watch today, according to MarketBeat's stock screener...

Billions in Play: The Hidden Land Grab Across AI, Biotech, and Precision Medicine

A fresh wave of dealmaking, platform expansion, and commercialization milestones is reshaping the narrative across emerging healthcare and AI-driven companies. $TGNT, $PFSA, $KBLB, $NBIX, $SLNO, $FCUV

<ul class="summary-bullets"><li>Profusa will gain exclusive rights to the PanOmics platform and related expertise, including access to samples and tools.</li><li>Profusa will pay BioInsights about $30 million in equity.</li><li>BioInsights will receive a 3% royalty on future net revenue.</li></ul>Shares of Profusa, Inc. (PFSA) surged 150% on Monday after the company announced plans to enter the molecular diagnostics space through a proposed acquisition of the PanOmics diagnostic platform from BioInsights.Under the agreement, Profusa would gain exclusive rights to the PanOmics platform and related expertise, including access to samples and tools, from BioInsights, for about $30 million. The consideration is payable in equity, the firm stated.BioInsights will receive a 3% royalty on future net revenue. The move is expected to add to Profusa’s real-time biochemistry monitoring technology.<h2 class="st-heading-2">Mayo Clinic Collaboration</h2>With access to clinical samples, a validation plan, and a partnership with the Mayo Clinic, the company believes it is well positioned to speed up development, increase clinical use, and create strong near-term growth.“The combination of the PanOmics platform and our collaboration with Mayo Clinic positions us to build a differentiated, scalable presence in precision diagnostics and surgical monitoring. The entry into pancreatic cancer is instrumental in our establishing a platform capable of supporting multiple indications and long-term growth,” said Ben Hwang, Profusa Chairman and CEO.&nbsp;<h2 class="st-heading-2">Potential For Recurring Revenue&nbsp;</h2>Combining the PanOmics platform with its biosensing technology could enable multi-indication diagnostics, real-time monitoring, and data-driven clinical tools, Profusa said. The company aims to expand into high-growth markets and build a scalable, recurring-revenue platform.&nbsp;It will also support its pancreatic cancer treatment efforts, using the Lumee oxygen system to improve monitoring during complex surgeries, a market with significant annual revenue potential.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/PFSA">PFSA</a> remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.One user expects the stock to be a multi-day runner following the news.<stembedurl>https://stocktwits.com/uppons/message/649485111</stembedurl>Another user expects the stock to rise to $1.94 due to strong volumes. It is currently at $1.85.<stembedurl>https://stocktwits.com/Twit_2_my_lou/message/649484322</stembedurl>Year-to-date, the stock has shed around 65%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did PFSA Stock Surge 150% Today?

Profusa announced plans to acquire the PanOmics diagnostic platform from BioInsights.

Equity

Why Applied Optoelectronics Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Applied Optoelectronics Inc (NASDAQ: AAOI) rose in pre-market trading after securing an 800G transceiver order worth $71 million, bringing total orders from a major customer to $124 million. Other...

Nio, Profusa, Nike, FTAI Aviation And Under Armour: Why These 5 Stocks Are On Investors' Radars Today

Profusa Stock Soars To 12 Cents On Debt Restructuring

Profusa stock soars after the company announced the restructuring of its debt and a reduction in potential shareholder dilution.read more...

Manufacturing Stocks To Add to Your Watchlist - December 30th

Taiwan Semiconductor Manufacturing, Applied Materials, Johnson Controls International, Profusa, FREYR Battery, Medline, and Phillips 66 are the seven Manufacturing stocks to watch today, according to...

Profusa, Inc. engages in the biofeedback for chronic disease management and healthy living services. The company is headquartered in Berkeley, CA.

Current Price	$0.4977
Prev Close	$0.577
Open	$0.577
Dividend Yield	0.00%
50-Day Moving Average	$0.9697
Beta	0.94
Avg. Volume	132,357.71
PE Ratio	0.00

52-Week High	$957.00
52-Week Low	$0.4101
Market Capitalization	$2.54M
EPS (Annual)	-$107.01
Price to Book	-0.03
Revenue Per Employee	N/A

PFSA
Profusa Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest PFSA News

PFSAProfusa Inc.